Senseonics 

$7.25
418
-$0.08-1.09% Today

Statistics

Day High
7.57
Day Low
7.15
52W High
26.2
52W Low
5.27
Volume
469,217
Avg. Volume
444,062
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.43
-0.3
-0.16
-0.02
Expected EPS
-0.432912
Actual EPS
N/A

Financials

-349.84%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
22.47MRevenue
-78.62MNet Income

Analyst Ratings

$18.38Average Price Target
The highest estimate is 31.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SENS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Dexcom
DXCM
Mkt Cap22.71B
Dexcom produces continuous glucose monitoring systems for diabetes management, directly competing with Senseonics' Eversense CGM system.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories offers the FreeStyle Libre, a flash glucose monitoring system, competing in the glucose monitoring space.
Tandem Diabetes Care
TNDM
Mkt Cap945.97M
Tandem Diabetes Care manufactures insulin pumps and integrated diabetes management systems, competing in the broader diabetes management market.
Insulet
PODD
Mkt Cap22.03B
Insulet Corporation develops the Omnipod, an insulin management system, which competes with diabetes management solutions like Senseonics'.
Medtronic
MDT
Mkt Cap116.33B
Medtronic offers the Guardian Sensor 3 CGM and insulin pumps, providing integrated diabetes management solutions.
Mirum Pharmaceuticals
MIRM
Mkt Cap3.65B
Mirum Pharmaceuticals, though more focused on liver diseases, has interests in metabolic disorders, potentially overlapping with diabetes management.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk specializes in diabetes care with insulin and GLP-1 receptor agonists, indirectly competing in diabetes management.
Sanofi
SNY
Mkt Cap124.45B
Sanofi produces insulin and other diabetes medications, competing in the broader market for diabetes management.
Merck
MRK
Mkt Cap214.76B
Merck & Co., with its diabetes medication portfolio, including Glucophage, competes in the pharmaceutical management of diabetes.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb, through its metabolic disorders treatment portfolio, indirectly competes in the diabetes management space.

About

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Show more...
CEO
Dr. Timothy T. Goodnow Ph.D.
Employees
117
Country
US
ISIN
US81727U3032

Listings

0 Comments

Share your thoughts

FAQ

What is Senseonics stock price today?
The current price of SENS is $7.25 USD — it has decreased by -1.09% in the past 24 hours. Watch Senseonics stock price performance more closely on the chart.
What is Senseonics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Senseonics stocks are traded under the ticker SENS.
Is Senseonics stock price growing?
SENS stock has risen by +2.26% compared to the previous week, the month change is a +23.09% rise, over the last year Senseonics has showed a -62.27% decrease.
When is the next Senseonics earnings date?
Senseonics is going to release the next earnings report on March 02, 2026.
What were Senseonics earnings last quarter?
SENS earnings for the last quarter are -0.43 USD per share, whereas the estimation was -0.37 USD resulting in a -14.84% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Senseonics revenue for the last year?
Senseonics revenue for the last year amounts to 22.47M USD.
What is Senseonics net income for the last year?
SENS net income for the last year is -78.62M USD.
How many employees does Senseonics have?
As of February 02, 2026, the company has 117 employees.
In which sector is Senseonics located?
Senseonics operates in the Health Care sector.
When did Senseonics complete a stock split?
The last stock split for Senseonics was on October 20, 2025 with a ratio of 1:20.
Where is Senseonics headquartered?
Senseonics is headquartered in Germantown, US.